Salicylate •Phenanthroline copper (II) complex induces apoptosis in triple-negative breast cancer cells
Metrics: PDF 771 views | HTML 1027 views | ?
Limei Fan1,2,*, Muyou Tian3,*, Yunyi Liu1,2,*, Ying Deng1,2, Zhengkai Liao3,4, Jinhua Xu1,2
1School of Medicine, Jianghan University, Wuhan, Hubei 430056, China
2Key Laboratory of Optoelectronic Chemical Materials and Devices, Ministry of Education, Jianghan University, Wuhan, Hubei 430056, China
3Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430071, China
4Hubei Key Laboratory of Tumor Biological Behavior, Wuhan University, Wuhan, Hubei 430071, China
*These authors contributed equally to this work
Yunyi Liu, email: firstname.lastname@example.org
Zhengkai Liao, email: email@example.com
Jinhua Xu, email: firstname.lastname@example.org
Keywords: TNBC, Cu(sal)(phen), cell growth, apoptosis, anti-apoptotic protein
Received: December 20, 2016 Accepted: March 03, 2017 Published: March 13, 2017
In this study, we investigated anti-tumor activity and associated molecular mechanism of action of Salicylate ●Phenanthroline Copper (II) Complex in triple-negative breast cancer. Salicylate ●Phenanthroline Copper (II) Complex inhibited the growth of four breast cancer cell lines (MCF-7, T47D, MDA-MB-231 and BT-20) and induced apoptosis in a concentration-dependent manner. The effect was more profound in MDA-MB-231 and BT-20 triple-negative breast cancer cell lines. Western blot showed that the expression of the apoptosis-related protein Bcl-2, Bcl-xl and survivin was significantly reduced in MDA-MB-231 after treatment with Salicylate ●Phenanthroline Copper (II) Complex. In vivo, Salicylate ●Phenanthroline Copper (II) Complex administration significantly attenuated tumor growth of MDA-MB-231 xenografts, and the expression levels of Bcl-2, Bcl-xL and survivin were reduced as measured by immunohistochemical staining. These data suggest that Salicylate ●Phenanthroline Copper (II) Complex is a promising novel therapeutic drug for triple-negative breast cancer and warrants further study.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.